This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Aberdeen Asset Management (ADN.L) – Pretax profit £217m down 3% (222.8m last year), EPS 14.3p, operating margin 43%, AuM £324bn, dividend 6.75p (up 12.5%) “sees signs of pickup in sentiment toward emerging markets. Closing Price 445.90p (Bloomberg)
AstraZeneca (AZN.L) – Has won FDA approval for Epanova, a new pill for heart disease. Closing Price 4808.00p (Reuters)
Barclays (BARC.L) – Pretax profit down to £1.69bn, investment banking income down 28% to £2.49bn, Q1 net profit to £965m (£934m expected) “focused on structurally reducing cost base”. Closing Price 258.50p (Bloomberg)
Balfour Beatty (BBY.L) – CEO Andrew McNaughton has quit as it warned that 2014 pre-tax profits would be significantly lower than previous expectations. Weakness in its British construction business expects £30m shortfall in 2014. Pretax profit range now £145-160m vs. £187m expected Closing Price 285.80p (Reuters)
Glencore Xstrata (GLEN.L) – Met market forecasts with a 24% increase in copper production in Q1 helped by production expansion at its African and Australian operations. Produced 382,000tns of copper in Q1 (321,800tns last year) Closing Price 319.25p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| AstraZeneca | AZN.L | -0.15% | 2.73% | -2.05% |
| InterContinental Hotels Group | IHG.L | 8.20% | 10.39% | 5.48% |
| Royal Bank of Scotland | RBS.L | 8.19% | 13.42% | 4.37% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research